Novo Nordisk Plunges 40%, Trades at 10.6x Versus Eli Lilly’s 45.4x
Novo Nordisk’s stock has slumped over 40% in the past month and 58% year-over-year, pushing its P/E down to 10.6x while Eli Lilly trades at 45.4x. That leaves Novo Nordisk yielding 9.4% versus Lilly’s 2.2%, establishing a deep-value contrast in obesity-drug leaders.
1. Steep Share Price Decline
Novo Nordisk’s stock has plunged more than 40% over the past month and 58% over the past year, collapsing from a 52-week high of $91.90 to near $38 per share. The sharp selloff reflects investor concern over pricing pressure, competitive threats and slowing GLP-1 growth expectations.
2. Valuation Disparity with Peers
With a P/E ratio of just 10.6x and earnings yield of 9.4%, Novo Nordisk trades at a material discount to obesity-drug rival Eli Lilly, which stands at 45.4x (2.2% yield), as well as Vertex Pharmaceuticals (31.8x) and Pfizer (20.0x). This gap underscores a shift from hyper-growth to legacy-pharma valuation.
3. Implications for Eli Lilly
Eli Lilly’s premium valuation suggests investors view it as a safer growth proxy in obesity-drug expansion, potentially attracting capital reallocated from Novo Nordisk. The relative stability of Lilly’s pipeline and broader product portfolio could reinforce its appeal.
4. Deep-Value Opportunity Thesis
The magnitude of Novo Nordisk’s valuation reset may signal a deep-value entry point, as its global obesity-drug market share and long-term growth drivers remain intact. At current earnings yields, risk-reward metrics favor long-term investors seeking exposure to GLP-1 therapeutics.